@article {Frankel:2009:1389-4501:104,
title = "Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma",
journal = "Current Drug Targets",
parent_itemid = "infobike://ben/cdt",
publishercode ="ben",
year = "2009",
volume = "10",
number = "2",
publication date ="2009-02-01T00:00:00",
pages = "104-109",
itemtype = "ARTICLE",
issn = "1389-4501",
url = "https://www.ingentaconnect.com/content/ben/cdt/2009/00000010/00000002/art00004",
doi = "doi:10.2174/138945009787354539",
keyword = "cutaneous T cell lymphoma, diphtheria toxin, Immunotoxin",
author = "Frankel, A. E. and Zuckero, S. L. and Mankin, A. A. and Grable, M. and Mitchell, K. and Lee, Y. J. and Neville, D. M. and Woo, J. H.",
abstract = "The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3 monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease. ",
}